| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Stephen Z Levine, Stefan Leuch. Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials. Schizophrenia research. vol 156. issue 1. 2014-12-22. PMID:24794879. |
treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials. |
2014-12-22 |
2023-08-13 |
Not clear |
| R Grohmann, R R Engel, H-J Möller, E Rüther, J W van der Velden, S Stübne. Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study. European archives of psychiatry and clinical neuroscience. vol 264. issue 2. 2014-10-09. PMID:23835526. |
type and frequency of severe adrs attributed to flupentixol were compared with haloperidol, clozapine, olanzapine, quetiapine, risperidone and amisulpride in a total of 56,861 schizophrenia inpatients exposed to these drugs. |
2014-10-09 |
2023-08-12 |
Not clear |
| Yu-Ting Wang, Nan-Ying Chiu, Shaw-Hwa Jou, Yen Kuang Yang, I Hui Lee, Ching-Cheng Wang, Kao Ching Chen, Yi-Cheng Lia. Effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone. International journal of psychiatry in clinical practice. vol 12. issue 3. 2014-06-17. PMID:24931656. |
effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone. |
2014-06-17 |
2023-08-13 |
Not clear |
| Yu-Ting Wang, Nan-Ying Chiu, Shaw-Hwa Jou, Yen Kuang Yang, I Hui Lee, Ching-Cheng Wang, Kao Ching Chen, Yi-Cheng Lia. Effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone. International journal of psychiatry in clinical practice. vol 12. issue 3. 2014-06-17. PMID:24931656. |
the aims of this 13-week study were to examine the efficacy and safety of amisulpride, and effects on cognitive function in patients with schizophrenia after they switched from risperidone. |
2014-06-17 |
2023-08-13 |
Not clear |
| Yu-Ting Wang, Nan-Ying Chiu, Shaw-Hwa Jou, Yen Kuang Yang, I Hui Lee, Ching-Cheng Wang, Kao Ching Chen, Yi-Cheng Lia. Effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone. International journal of psychiatry in clinical practice. vol 12. issue 3. 2014-06-17. PMID:24931656. |
twenty-three patients with schizophrenia whose antipsychotic was switched from risperidone to amisulpride were recruited. |
2014-06-17 |
2023-08-13 |
Not clear |
| Yu-Ting Wang, Nan-Ying Chiu, Shaw-Hwa Jou, Yen Kuang Yang, I Hui Lee, Ching-Cheng Wang, Kao Ching Chen, Yi-Cheng Lia. Effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone. International journal of psychiatry in clinical practice. vol 12. issue 3. 2014-06-17. PMID:24931656. |
switching antipsychotic from risperidone to amisulpride in schizophrenia might have significantly improved not only the efficacy, but also various domains of cognitive function. |
2014-06-17 |
2023-08-13 |
Not clear |
| Nikhiles Mandal, Om P Singh, Subrata Se. Extrapyramidal side effects with low doses of amisulpride. Indian journal of psychiatry. vol 56. issue 2. 2014-06-03. PMID:24891713. |
amisulpride, the newly introduced antipsychotic in india, is claimed to be effective in both positive and negative symptom schizophrenia and related disorders, though it has little or no action on serotonergic receptors. |
2014-06-03 |
2023-08-13 |
Not clear |
| Ching-Hua Lin, Fu-Chiang Wang, Shih-Chi Lin, Yu-Hui Huang, Cheng-Chung Chen, Hsien-Yuan Lan. Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study. International clinical psychopharmacology. vol 28. issue 5. 2014-03-10. PMID:23778382. |
this study aimed to compare the efficacy and safety of low-dose amisulpride plus low-dose sulpiride with full-dose amisulpride in the treatment of acute schizophrenia. |
2014-03-10 |
2023-08-12 |
Not clear |
| Ali Evren Tufan, Irem Yalu. Clozapine augmented with amisulpride in 3 cases of treatment-resistant early- and very early-onset schizophrenia. Journal of clinical psychopharmacology. vol 33. issue 4. 2014-02-18. PMID:23764685. |
clozapine augmented with amisulpride in 3 cases of treatment-resistant early- and very early-onset schizophrenia. |
2014-02-18 |
2023-08-12 |
Not clear |
| Agnieszka Nikiforuk, Tomasz Kos, Katarzyna Fijał, Małgorzata Hołuj, Dominik Rafa, Piotr Popi. Effects of the selective 5-HT7 receptor antagonist SB-269970 and amisulpride on ketamine-induced schizophrenia-like deficits in rats. PloS one. vol 8. issue 6. 2014-01-16. PMID:23776692. |
because the role of 5-ht7 receptor blockade in ameliorating positive and negative symptoms of schizophrenia remains equivocal, the second aim of these experiments was to examine the effectiveness of sb-269970 and amisulpride in reversing ketamine-induced deficits in prepulse inhibition of the startle reflex and in social interaction test in rats. |
2014-01-16 |
2023-08-12 |
rat |
| W Wolfgang Fleischhacker, Cynthia O Siu, Robert Bodén, Elizabeth Pappadopulos, Onur N Karayal, René S Kah. Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. The international journal of neuropsychopharmacology. vol 16. issue 5. 2014-01-03. PMID:23253821. |
in this study, we assessed the baseline prevalence of metabolic abnormalities and changes following treatment with five commonly-used antipsychotic drugs (haloperidol, amisulpride, olanzapine, quetiapine or ziprasidone) in first-episode, partially antipsychotic-naive patients with schizophrenia in the european first-episode schizophrenia trial (eufest). |
2014-01-03 |
2023-08-12 |
human |
| Anirban Ray, Santanu Munsh. Augmenting amisulpride with clozapine had led to unmasking of akathisia. Industrial psychiatry journal. vol 21. issue 2. 2013-11-19. PMID:24250050. |
amisulpride is a newer antipsychotic, which is very effective on its own, as well as augmenting other antipsychotic clozapine, which is an effective molecule for treatment resistant schizophrenia. |
2013-11-19 |
2023-08-12 |
Not clear |
| David N Osser, Mohsen Jalali Roudsari, Theo Manschrec. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia. Harvard review of psychiatry. vol 21. issue 1. 2013-10-29. PMID:23656760. |
the first-line treatment recommendation for new-onset schizophrenia is with amisulpride, aripiprazole, risperidone, or ziprasidone for four to six weeks. |
2013-10-29 |
2023-08-12 |
Not clear |
| Frederike Schirmbeck, Franziska Rausch, Susanne Englisch, Sarah Eifler, Christine Esslinger, Andreas Meyer-Lindenberg, Mathias Zin. Differential effects of antipsychotic agents on obsessive-compulsive symptoms in schizophrenia: a longitudinal study. Journal of psychopharmacology (Oxford, England). vol 27. issue 4. 2013-09-09. PMID:23095245. |
over 12 months, we followed-up 75 schizophrenia patients who were classified into two groups according to antipsychotic treatment: clozapine or olanzapine (group i) versus aripiprazole or amisulpride (group ii). |
2013-09-09 |
2023-08-12 |
Not clear |
| Zeynep Kotan, Berrin Ertepe, Cengiz Akkaya, Emre Sarandol, Güven Ozkaya, Selçuk Kirl. Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study. Therapeutic advances in psychopharmacology. vol 1. issue 6. 2013-08-28. PMID:23983946. |
amisulpride is a second-generation antipsychotic which has been proved to be effective in the control of both positive and negative symptoms of schizophrenia. |
2013-08-28 |
2023-08-12 |
Not clear |
| G V Idova, E L Al'perina, O A Lobacheva, E N Zhukova, M A Cheĭdo, T A Meniavtseva, T P Vetlugin. [Effect of antipsychotic amisulpride on immune reactivity]. Eksperimental'naia i klinicheskaia farmakologiia. vol 76. issue 5. 2013-08-27. PMID:23901463. |
in addition, the effect of solian on the expression of various cd-markers of lymphocytes in has been analyzed in vitro for patients with schizophrenia diagnosis. |
2013-08-27 |
2023-08-12 |
mouse |
| G V Idova, E L Al'perina, O A Lobacheva, E N Zhukova, M A Cheĭdo, T A Meniavtseva, T P Vetlugin. [Effect of antipsychotic amisulpride on immune reactivity]. Eksperimental'naia i klinicheskaia farmakologiia. vol 76. issue 5. 2013-08-27. PMID:23901463. |
in the in vitro system, solian produced opposite effects on the expression of surface cd receptors in lymphocytes of patients with schizophrenia. |
2013-08-27 |
2023-08-12 |
mouse |
| Janusz K Rybakowski, Kristof Vansteelandt, Tomasz Szafranski, Eric Thys, Marek Jarema, W Wolfgang Fleischhacker, René S Kahn, Joseph Peusken. Treatment of depression in first episode of schizophrenia: results from EUFEST. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 22. issue 12. 2013-08-26. PMID:22627166. |
this reanalysis of the european first episode schizophrenia trial (eufest) describes the depressive symptomatology and the effect of antipsychotic treatment in patients suffering from first episode schizophrenia and schizophreniform disorder randomized to treatment with low dose haloperidol (n=103), amisulpride (n=104), olanzapine (n=105), quetiapine (n=104) or ziprasidone (n=82) for one year. |
2013-08-26 |
2023-08-12 |
Not clear |
| Seung Jae Lee, Jong Hun Lee, Sung Won Jung, Bon Hoon Koo, Tae Young Choi, Kwang Hun Le. A 6-week, randomized, multicentre, open-label study comparing efficacy and tolerability of amisulpride at a starting dose of 400 mg/day versus 800 mg/day in patients with acute exacerbations of schizophrenia. Clinical drug investigation. vol 32. issue 11. 2013-07-11. PMID:23018281. |
a 6-week, randomized, multicentre, open-label study comparing efficacy and tolerability of amisulpride at a starting dose of 400 mg/day versus 800 mg/day in patients with acute exacerbations of schizophrenia. |
2013-07-11 |
2023-08-12 |
Not clear |
| Ganesh R Pawar, P Phadnis, A Paliwa. Evaluation of efficacy, safety, and cognitive profile of amisulpride per se and its comparison with olanzapine in newly diagnosed schizophrenic patients in an 8-week, double-blind, single-centre, prospective clinical trial. ISRN psychiatry. vol 2012. 2013-06-06. PMID:23738210. |
to compare efficacy, safety, and cognitive profile of amisulpride and olanzapine in the treatment of acute psychotic exacerbations of schizophrenia. |
2013-06-06 |
2023-08-12 |
human |